Pharma & API Trade Data: Find Medicine Buyers in 2026

Roughly one in five generic medicines on Earth — by volume — comes out of a factory in India, yet most of the companies making them have never seen the full list of foreign buyers actually importing their molecule. They sell to the same three distributors a broker introduced them to in 2019, and call it a market strategy.

That gap is the whole opportunity. The pharmaceutical and nutraceutical trade is enormous, fragmented, and almost entirely visible in shipment records — if you know where to look. This is how an SME exporter of APIs, formulations, excipients or supplements turns 11 billion shipment records into an actual buyer list.

Why pharma is the most data-legible trade there is

Medicines move across borders under tightly defined HS codes — Chapter 30 for formulations and finished dosage forms, Chapter 29 for the organic chemicals that include most active pharmaceutical ingredients. Every shipment of paracetamol, ibuprofen, metformin, amoxicillin or azithromycin generates a bill-of-lading record somewhere in the world: a consignee, a quantity, a port, a date. Multiply that across India's 200-plus export markets and you get a near-complete map of who buys what, in what volume, from whom.

The headline numbers explain why this matters. India's pharmaceutical exports reached $30.47 billion in FY2024-25, a 9.4% jump over the prior year's $27.85 billion. The country earned its "pharmacy of the world" label honestly: it provides around 20% of the global generic medicine supply by volume and meets 55–60% of UNICEF's vaccine demand, including 99% of the WHO's DPT requirement. That covers everything from oncology generics and antibiotics to vitamins, dietary supplements and the formulations built on top of imported intermediates.

The markets that actually pay

Export value is not evenly spread. The United States is the single dominant destination, absorbing $8.95 billion — over a third of all Indian pharma exports in FY25, up 14.3% year-on-year. After the US come the UK, Brazil, France and South Africa. In the US specifically, Indian firms supplied 47% of all generic prescriptions and delivered an estimated $219 billion in healthcare savings in a single year. Africa and the EU round out the high-volume regions — and each has its own importer ecosystem you can isolate in trade data.

The China dependency that defines 2026

Here is the structural weakness every API buyer and seller should be tracking: India may dominate finished generics, but it imports roughly 70% of the bulk drugs and APIs needed to make them — overwhelmingly from China. In March 2026, India's Department of Pharmaceuticals tabled a list in Parliament of APIs where China accounts for 70% or more of imports; for essential antibiotics like penicillin, azithromycin and the cephalosporins, the dependence tops 90%. Vitamins, fermentation-based products and chemical intermediates are similarly exposed.

For every player in this market — whether you sell APIs, source intermediates, or manufacture formulations — the "China Plus One" shift is not a slogan. It is a live, traceable change in who is shipping what, to whom, and from where.

The policy response is producing measurable movement. Under the bulk-drugs PLI scheme, India had created domestic capacity for 26 APIs, key starting materials and intermediates by mid-2025, with cumulative investment past ₹4,700 crore and import substitution worth ₹1,483 crore. Translation: new domestic API suppliers are entering the market, and importers worldwide are actively diversifying away from single-source Chinese supply. Both sides of that trade show up in shipment records before they show up in any industry report.

The tariff clock

The other 2026 wildcard is American trade policy. On April 2, 2026, a Section 232 proclamation imposed tariffs of up to 100% on patented pharmaceuticals and their ingredients, phasing in from July 31 through September 29, 2026. Generic medicines and biosimilars are explicitly exempt for now — a real reprieve for India — but Commerce must advise within a year whether to extend the tariffs to generics too. Exporters who can see which US importers are most exposed, and which alternative markets are absorbing volume, will move first. Everyone else reads about it after the fact.

How ShipScout turns this into a buyer list

Knowing the macro picture is worthless without the names. ShipScout indexes 11 billion-plus shipment records across 240+ countries at a fraction of what ImportGenius or Panjiva charge — built for SME exporters and importers, not enterprise procurement teams. Here is the practical workflow for a pharma or nutraceutical business.

Find buyers by HS code. Start with the molecule. Search the HS code for your API or formulation — paracetamol, metformin, an amoxicillin intermediate, an insulin analog, a vitamin premix — and pull every importer pulling that code into your target market. Filter by country to isolate, say, every US, German or Brazilian consignee buying your excipient or biosimilar. Browse the live global company directory to start, or jump straight to a market like the United States importer list or Brazil to see who is active right now.

Rank importers by volume. A list of 400 buyers is noise. Rank them by shipment volume and frequency so your sales team calls the top 30 consignees actually moving meaningful quantities — not the one-off sampler who imported a single drum two years ago.

Vet suppliers before you commit. Sourcing APIs or excipients from a new vendor? Check their actual export history — destinations, volumes, consistency, and whether their supply is concentrated in a single region. For anyone executing a China Plus One sourcing shift, this is how you confirm a prospective Indian or European API supplier can really deliver at scale before you sign.

Track competitors. Watch which buyers a rival exporter is shipping to, spot when a major importer switches suppliers, and catch new markets opening up — the moment a new oncology generic or biosimilar starts crossing a border, it is in the data.

The pharmaceutical trade is one of the few large markets where almost the entire buyer and supplier universe is already documented in shipment records. The exporters who win in 2026 will not be the ones with the cheapest paracetamol. They will be the ones who knew exactly who was buying it — and from whom — before their competitors did.